CRISPR-Cas9-Guided Genetic Manipulation of Patient-Derived Brain Tumor Cells.

Yujin Suk, Erika Apel, Stefan Custers, Petar Miletic, Kui Zhai, Chirayu Chokshi, Chitra Venugopal, Jason Moffat, Sheila K Singh

Abstract read

PubMed Publisher

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yujin SukCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.

Erika ApelCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.

Stefan CustersCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.

Petar MileticCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.

Kui ZhaiCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.

Chirayu ChokshiCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.

Chitra VenugopalCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.

Jason MoffatDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

Sheila K SinghCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-Cas9 technology has revolutionized scientific research and has provided scientists with the ability to change DNA bases specifically and precisely at predetermined sites. The CRISPR-Cas9 knockout (KO) and activation (a) platforms developed by Hart et al. and Sanson et al. allow for RNA-directed genome editing to both decrease or increase gene expression, respectively [1, 2]. In this chapter the two techniques, CRISPR KO and CRISPRa, will be discussed and explained in further detail for optimized application against patient derived brain tumor cells.

Indexed as

Brain NeoplasmsCRISPR-Cas SystemsGene EditingCell Line, TumorGene Knockout TechniquesHumansRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsCas9CloningCRISPRGene activationGene editingGene knock outTransductionTransfection

Identifiers

PMID40553283

DOI10.1007/978-1-0716-4654-0_14

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.